louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03072745: Insomnia and Cognitive Performance in Chronic Pain
Official title: Distinct Effect of Insomnia on Cognitive Performance in Individuals With Complex Chronic Pain
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Chronic Pain
Insomnia
Keywords: Cognitive Impairment
Lead sponsor: Uppsala University
Sponsor class: OTHER
First posted: 2017-03-07
Enrollment: 22
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SCREENING

Brief summary: The aim of the present study is to examine cognitive function in a patient population with complex chronic pain to test the hypothesis that insomnia severity on its own predicts objective cognitive function, and that a correlation is not better explained by comorbid depression or anxiety, morphine equivalent daily dose, or the level of pain itself.

Detailed description: Almost 20 % of the adult European population suffers from chronic pain of moderate to severe intensity, and clinical insomnia has been reported in 53-73% of chronic pain patients. Insomnia seems to be correlated with small to moderate impairments in several cognitive functions involved in working and episodic memory and in attention tasks, and chronic pain has been shown to be associated with objective deficits in memory and executive functioning. The aim of the present study is to examine cognitive function in a patient population with complex chronic pain to test the hypothesis that insomnia severity on its own predicts objective cognitive function, and that a correlation is not better explained by comorbid depression or anxiety, morphine equivalent daily dose, or the level of pain itself.

Inividuals with complex chronic pain are assessed with a neuropsychological test battery examining different aspects of memory and executive functioning:

The Digit Span subtest from Wechsler's Adult Intelligence Scale III (WAIS-III): Verbal working memory.

Claeson-Dahl Inventory of Learning and Memory (CD): Verbal retention. The Rey Complex Figure Test (RCFT): Visuospatial retention. The Wisconsin Card Sorting Test (WCST): Cognitive flexibility. The Trail-Making Test (TMT): Sustained attention.

The presence of insomnia is examined with the Bergen Insomnia Scale (BIS) , and insomnia severity with the Insomnia Severity Index (ISI). Present pain level at the time of the neuropsychological assessment is quantified using the Visual Analogue Scale (VAS). Pain medication is transformed to the morphine equivalent daily dose (MEDD). Anxiety and depression are assessed with the Hospital Anxiety and Depression Scale.

Eligibility criteria: Inclusion Criteria:

* Attending tertiary chronic pain management

Exclusion Criteria:

* None

Primary outcomes:
measure: Memory impairment
timeFrame: 1 day
Secondary outcomes:
measure: Executive functioning impairment
timeFrame: 1 day
Other outcomes:
Locations:
city: Uppsala
country: Sweden
facility: Uppsala University
Study officials:
affiliation: Uppsala University
name: Torsten Gordh, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03375645: Montefiore Opioid and Pain Study
Official title: Montefiore Opioid and Pain Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Acute Pain
Lead sponsor: Montefiore Medical Center
Sponsor class: OTHER
First posted: 2017-12-18
Enrollment: 462
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Emergency department patients who are evaluated for acute pain and are prescribed an oral opioid

Brief summary: This study will determine pain and opioid outcomes 3 \& 6 months after an emergency department visit for acute pain. This is an observational study. Patients are enrolled during an ED visit and followed by telephone 3 \& 6 months later. Opioid databases will also be reviewed.


Eligibility criteria: Inclusion Criteria:

* Adults seen in the emergency department for acute, new-onset pain, defined as: 1)localized pain duration \< 10 days and 2) prior to the acute episode, the patient has not had this type of pain in the preceding six months
* Upon emergency department discharge, the patients is prescribed an opioid for pain

Exclusion Criteria:

* Any prescribed opioid use within the previous six months including methadone and buprenorphine

  * Frequent use of any analgesic medication (Use of any analgesic \>10 days per month prior to the onset of acute pain)
  * Not available for follow-up

Primary outcomes:
measure: Subsequent opioid prescription
timeFrame: 6 months
measure: Chronic pain in the affected body part
timeFrame: 6 months
Secondary outcomes:
measure: 3 item PEG score
timeFrame: 3 months and 6 months after ED discharge
measure: Pain description
timeFrame: 3 months and 6 months after ED discharge
Other outcomes:
Locations:
city: Bronx
country: United States
facility: Montefiore Medical Center
state: New York
Study officials:
affiliation: Montefiore Medical Center
name: Benjamin Friedman, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06628245: The Dubousset Functional Test in Lumbar Spinal Stenosis
Official title: Validity and Reliability of Dubousset Functional Test in Lumbar Spinal Stenosis
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Lumbar Spinal Stenosis
Keywords: Lumbar Spinal Stenosis
Functional Status
Dubousset Functional Test
Reliability
Validity
Lead sponsor: Alanya Alaaddin Keykubat University
Sponsor class: OTHER
First posted: 2024-10-04
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Sixty patients with lumbar spinal stenosis.

Brief summary: The aim of this study is to investigate the validity and reliability of Dubousset Functional Test in the patients with lumbar spinal stenosis.


Eligibility criteria: Inclusion Criteria:

* Patients aged 18-65 years, diagnosed with chronic pain (more than three months) due to lumbar spinal stenosis.

Exclusion Criteria:

* Those with fractures, pregnancy, a disease that would prevent physical exertion, those with a body mass index (BMI) of 40 kg/m2 and above, and those with major musculoskeletal or neurological disorders that cause gait disturbance will be excluded from the study.

Primary outcomes:
measure: Dubousset Functional Test
timeFrame: 10 minutes
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05885945: Diaphragmmatic Muscle Strength and Balance in Women With Dysmenorhea
Official title: Diaphragmmatic Muscle Strength and Balance in Women With Dysmenorhea
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Dysmenorrhea Primary
Keywords: dysmenorrhea
diaphragm
balance
muscular strength
Lead sponsor: Catholic University of Murcia
Sponsor class: OTHER
First posted: 2023-06-02
Enrollment: 23
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Women with primary dysmenorrhea

Brief summary: Analysis of stabilometric and respiratory variables in patients with dysmenorrhea during the first day of the menstrual cycle and any other day outside the cycle.

Detailed description: Sociodemographic variables such as age, height, body mass index.

Respiratory variables such as maximum inspiratory pressure (MIP), MIP reference %, and MIP predictive value.

Stabilometric variables we will measure the balance in condition of eyes open and eyes closed bipodal support and eyes open in monopodal support

Eligibility criteria: Inclusion Criteria:

* Adult women with primary dysmenorrhea.
* Not having had any type of childbirth (natural, caesarean section, etc).
* Not be positive in COVID. Antigen test in the last 24 hours or negative PCR in the last 48 hours.

Exclusion Criteria:

* Receive medical treatment during research.
* Have any orthopedic, neurological or systemic disease diagnosed other than primary dysmenorrhea.
* Be in follow-up with any medical treatment that does not be primary dysmenorrhea
* Women with a history of trauma or surgical treatment who involve the musculoskeletal system in the last year.
* Use of analgesics in the last 48 hours.
* Consumption of alcohol in the last 24 hours.
* Have a history or suspicion of pregnancy.

Primary outcomes:
measure: Balance
timeFrame: 2 months
measure: diaphragmatic muscle strength
timeFrame: 2 months
Secondary outcomes:
measure: sociodemographic variables
timeFrame: 2 monsths
Other outcomes:
Locations:
city: Guadalupe
country: Spain
facility: University Catholic of Murcia
state: Murcia
Study officials:
affiliation: Catholic University of Murcia
name: Felipe León-Morillas
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01907945: Healthy Networks Water Treatment Study
Official title: Healthy Networks Water Treatment Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Household Water Treatment
Waterborne Illness
Keywords: Household water treatment
Waterborne illness
ceramic filters
social network
Lead sponsor: University of California, San Francisco
Sponsor class: OTHER
Collaborators: name: Organic Health Response
name: Microclinic International
name: Kenya Medical Research Institute
First posted: 2013-07-25
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: This study is a non-randomized double cohort study evaluating the impact of social network-based water treatment education on sustained household water treatment behaviors over 12 months of follow up. A three-session curriculum was developed on the spread of water borne illness, water treatment methods, and the role of social support in water treatment. Participants in the intervention arm will receive this curriculum in a group setting, where group members are self-selected members of the study participants' social networks. Participants in the comparison arm will receive the same curriculum taught at the individual household level. All participants will receive CeraMaji ceramic filters for use in household water treatment after participating in the three sessions. Research staff will conduct surveys and water quality testing over a period of 12 months to determine whether participants continue to use the ceramic filters. Investigators hypothesize that social network-based training on household water treatment will result in a higher proportion of households using ceramic filters at 6- and 12-months as compared to households receiving individual training.


Eligibility criteria: Inclusion Criteria:

* Participant in the Mfangano Island Healthy Networks Impact Study
* Resident of Mfangano Island in the East or North sub-locations
* 18 years of age or older
* Conversant in DhoLuo or English

Exclusion Criteria:

* none

Primary outcomes:
measure: Ceramic filter use
timeFrame: 6 months post-intervention
measure: Ceramic filter use
timeFrame: 12 months post-intervention
Secondary outcomes:
measure: Fecal coliforms
timeFrame: 6 months post-intervention
measure: Fecal coliforms
timeFrame: 12 months post-intervention
Other outcomes:
Locations:
city: Kitawi Beach, Mfangano Island
country: Kenya
facility: Ekialo Kiona Center
state: Nyanza
Study officials:
affiliation: University of California, San Francisco
name: Craig R Cohen, MD, MPH
role: PRINCIPAL_INVESTIGATOR
affiliation: Kenya Medical Research Institute
name: Elizabeth Bukusi, MBChB, M.Med
role: PRINCIPAL_INVESTIGATOR
affiliation: University of California, San Francisco
name: Matthew D Hickey, MD Candidate
role: PRINCIPAL_INVESTIGATOR
affiliation: University of California, San Francisco
name: Charles R Salmen, MSc, MD candidate
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05615545: Cryoablation for Advanced Bone and Soft Tissue Tumors
Official title: Safety and Efficacy of Cryoablation in the Treatment of Advanced Bone and Soft Tissue Tumors: a Single-center Retrospective Study
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Sarcoma
Cryoablation
Lead sponsor: Henan Cancer Hospital
Sponsor class: OTHER_GOV
First posted: 2022-11-14
Enrollment: 30
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Cryoablation of selected tumor lesions in patients with metastatic/operatively unresectable bone and soft tissue sarcomas

Brief summary: This is a single-center, open, retrospective clinical study of patients with metastatic/surgically unresectable bone and soft tissue sarcoma undergoing cryoablation of selected tumor lesions. All eligible patients were enrolled. Basic data and treatment methods of these patients were collected, and efficacy and safety were evaluated.

Detailed description: This is a single-center, open, retrospective clinical study of patients with metastatic/surgically unresectable bone and soft tissue sarcoma undergoing cryoablation of selected tumor lesions. Clinical data of eligible patients were scheduled to be retrospectively collected from December 2016 to February 28, 2022. All patients eligible for inclusion. Basic data and treatment methods of these patients were collected, and efficacy and safety were evaluated.

Eligibility criteria: Inclusion Criteria:

No age restriction, male or female.

The pathological diagnosis was a subtype of bone and soft tissue sarcoma.

The clinical stage was determined to be metastatic or locally unresectable bone and soft tissue sarcoma.

At least one cryoablation of tumor lesions was performed in our hospital.

Target lesions can be evaluated according to the efficacy evaluation criteria for solid tumors (RECIST; Version 1.1) Measure diameter changes.

Follow-up data were complete.

Exclusion Criteria:

Not applicable.

Primary outcomes:
measure: Survival rates
timeFrame: 12 months after surgery
measure: There was no local recurrence survival rate
timeFrame: 12 months after surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Zhengzhou
country: China
facility: Department of Bone and Soft Tissue ,Henan Cancer Hospital
state: Henan
Study officials:
References:
Clinical trial NCT04138745: Transverse Thoracic Plane Block in the Pediatric Cardiac Patient
Official title: Transverse Thoracic Plane Block in the Pediatric Cardiac Patient
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pain, Acute
Congenital Heart Disease
Lead sponsor: Ochsner Health System
Sponsor class: OTHER
First posted: 2019-10-24
Enrollment: 200
Sex: ALL
Minimum age (years): 0
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: All comers int he age groups above

Brief summary: Postoperative pain after cardiothoracic surgery can be a significant problem interfering with recovery, yet difficult to manage due to the sedating effects of opiates. These patients frequently have associated postoperative pulmonary changes and are at risk of respiratory depression with opioid analgesia. The ultrasound-guided transversus thoracic muscle plane block (TTMPB) is a recently described regional anesthetic technique showing improvements in postoperative pain management. Further investigation is needed to establish the potential of the TTMPB as an analgesic modality in congenital cardiothoracic surgery in patients under the age of 18.


Eligibility criteria: Inclusion Criteria:

* Congenital Heart Surgery

Exclusion Criteria:

* Over 18

Primary outcomes:
measure: Extubation
timeFrame: 2 years
Secondary outcomes:
measure: Surgical Stress Response
timeFrame: 2 years
measure: Opiate Usage
timeFrame: 2 years
Other outcomes:
Locations:
city: New Orleans
country: United States
facility: Ochsner Health System
state: Louisiana
Study officials:
affiliation: Ochsner Health System
name: DOMINIC S CAROLLO, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03166345: Use of Platelet Rich Plasma (PRP) for Improving Thin Endometrium
Official title: Use of Platelet Rich Plasma (PRP) for Improving Thin Endometrium For IVF Women
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Poor Endometrium
Lead sponsor: Ibn Sina Hospital
Sponsor class: OTHER_GOV
Collaborators: name: Ganna Hospital
First posted: 2017-05-25
Enrollment: 150
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: Platelets rich plasma is simple source of growth factors and cytokines that can regulate endometrial growth for subgroup of thin endometrium women. It is an autologous source of this enhancing factors; therefore, there os no risk of using it within the same participant.


Eligibility criteria: Inclusion Criteria:

* women with thin endometrium

Exclusion Criteria:

* serum positive hepatitis B and C women

Primary outcomes:
measure: Mean Diameter of endometrial thickness
timeFrame: 2 days
Secondary outcomes:
measure: Clinical pregnancy rate
timeFrame: 4 weeks or beyond after embryo Transfer
Other outcomes:
Locations:
city: Giza
country: Egypt
facility: Gannah IVF unit, Gannah Hospital
city: Sohag
country: Egypt
facility: IbnSina IVF Center, IbnSina Hospital
Study officials:
affiliation: Ganna Hospital
name: Ayman S El-Gohary, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00814645: Dose-Finding, Safety, Pharmacodynamic Effect Study of Sodium Nitrite Inhalation Solution in Normal, Healthy Volunteers
Official title: A Placebo-Controlled, Phase 1b, Dose-Finding, Safety, Pharmacodynamic Effect Study of Sodium Nitrite Inhalation Solution (AIR001 INHALATION SOLUTION) in Normal, Healthy Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Pulmonary Arterial Hypertension
Lead sponsor: Aires Pharmaceuticals, Inc.
Sponsor class: INDUSTRY
First posted: 2008-12-25
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is designed to investigate the safety and tolerability of AIR001 Inhalation Solution when administered under conditions of hypoxia and to identify dose levels of drug resulting in a reduction in pulmonary arterial pressure under these hypoxic conditions.


Eligibility criteria: Inclusion Criteria:

* Normal male and female volunteers
* Age 18-55
* Demonstrate a rise in pulmonary artery pressure to low inspired oxygen concentration (a normal response to breathing a low level of oxygen)

Exclusion Criteria:

* Significant medical illnesses
* Risk factors for pulmonary hypertension
* G6PD or Cytochrome B5 Reductase deficiencies
* History of any form of altitude sickness
* Current prescription or over the counter medication use

Primary outcomes:
measure: The measurement of pulmonary arterial pressures by echocardiography.
timeFrame: Pretreatment and up to 2 hours post treatment
Secondary outcomes:
measure: Plasma pharmacokinetics
timeFrame: Pretreatment to 8 hours post treatment
measure: Hematology, blood chemistry, coagulation and urinalysis, methemoglobin, oxygen saturation, electrocardiogram, troponin, and vital signs and adverse events.
timeFrame: Pretreatment, post treatment, and 24 hours post treatment
Other outcomes:
Locations:
city: Minneapolis
country: United States
facility: DaVita Clinical Research
state: Minnesota
Study officials:
affiliation: Davita Clinical Research
name: Suzanne K Swan, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00005445: Epidemiology of Pediatric Asthma Hospitalization
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Asthma
Lung Diseases
Lead sponsor: Dartmouth-Hitchcock Medical Center
Sponsor class: OTHER
Collaborators: name: National Heart, Lung, and Blood Institute (NHLBI)
First posted: 2000-05-26
Sex: MALE
Maximum age (years): 100
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no

Brief summary: To study three possible, but yet unproven, influences on pediatric asthma hospitalization rates - diagnostic substitution, different systems of medical care, and asthma medication use.

Detailed description: BACKGROUND:

Recent research has shown that asthma admission rates for children vary widely across geographic areas and have increased nationally for the past decade. The results from these studies will have direct relevance to the clinical care and development of public policy for children with asthma.

DESIGN NARRATIVE:

Specific hypotheses regarding these factors which influence pediatric asthma hospitalization were tested in two different data sets: ecologic studies of trends and area variations of the children residing in the contiguous states of Maine, New Hampshire, and Vermont for 1980 - 1994; retrospective cohort analyses of children enrolled at a staff model HMO, Group Health Cooperative of Puget Sound for 1977 - 1994. These studies utilized detailed information regarding area and individual 'exposure' to differing systems of health care and asthma medications, controlling for socioeconomic status.

Eligibility criteria: No eligibility criteria

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
citation: Goodman DC, Fisher E, Stukel TA, Chang C. The distance to community medical care and the likelihood of hospitalization: is closer always better? Am J Public Health. 1997 Jul;87(7):1144-50. doi: 10.2105/ajph.87.7.1144.
citation: Goodman DC, Littenberg B, O'Connor GT, Brooks JG. Theophylline in acute childhood asthma: a meta-analysis of its efficacy. Pediatr Pulmonol. 1996 Apr;21(4):211-8. doi: 10.1002/(SICI)1099-0496(199604)21:43.0.CO;2-R.
citation: Goodman DC, Lozano P, Stukel TA, Chang Ch, Hecht J. Has asthma medication use in children become more frequent, more appropriate, or both? Pediatrics. 1999 Aug;104(2 Pt 1):187-94. doi: 10.1542/peds.104.2.187.
citation: Goodman DC, Stukel TA, Chang CH. Trends in pediatric asthma hospitalization rates: regional and socioeconomic differences. Pediatrics. 1998 Feb;101(2):208-13. doi: 10.1542/peds.101.2.208.
citation: Goodman DC, Fisher ES, Bubolz TA, Mohr JE, Poage JF, Wennberg JE. Benchmarking the US physician workforce. An alternative to needs-based or demand-based planning. JAMA. 1996 Dec 11;276(22):1811-7. doi: 10.1001/jama.276.22.1811.